Document:

Exhibit 10.10 Nutra Pharma Corp.

Exhibit 10.10

                                    XENACARE

Alan Xenakis, MD, ScD, MPH
President/CEO
7700 Congress Avenue
Suite 3208
Boca Raton, Florida  33487
561-999-0126

To:      Rik J. Deitsch, Ph.D.
From:    Alan P. Xenakis, MD
Date:    September 28, 2004
RE:      Letter of Intent between XenaCare and NutraPharma
--------------------------------------------------------------------------

Dear Dr. Deitsch:

Thank you for the opportunity to provide Site of Care Investment and Dividend
Reinvestment Management Services to NutraPharma.

This Letter of Intent (LOI) summarizes the conversations with XenaCare (Frank
Rizzo and myself), our mutual staffs and you from February 22, 2004 to September
24, 2004. This LOI will serve as the basis of the agreement between us.

XenaCare (Manager) will perform services as described in the original exhibit
attached to this letter for NutraPharma (Investor).

In summary, XenaCare will make all decisions to invest in the opening of 15
Sites of Care reflecting current costs of opening sites of care at a $250,000
investment and other use of Investor's investment at the Manager's sole
discretion without the requirement of first consulting with the Investor for
each opening.

Such investment may include, but not limited to, operating systems that help
productivity and revenue generation of non-prescription pharmaceutical sales at
the Site of Care such as training, marketing, and audio/teleconferencing and
database management. Investor recognizes the Manager's expertise and gives
Manager full power and authority to carry out these decisions on Investor's
behalf.

Providing NutraPharma follows this letter of Intent, these services will begin
on November 22, 2004 and will continue at the level appropriate to the schedule
of Investment and Reinvestment by the Investor.

Page two - Letter of Intent, September 28, 2004

In consideration for XenaCare's performance of these services, NutraPharma
agrees to invest a minimum of $25,000 on or before each of the following dates:
October 22, 2004, November 22, 2004, and December 23, 2004. Further, NutraPharma
will place into XenaCare LLC's account the remainder of the $250,000 in one lump
sum without prepayment penalty no later than February 15, 2005.

XenaCare and NutraPharma have agreed that the Investment will follow the
enclosed Dividend Reinvestment Plan. Under no circumstances, however, will
NutraPharma be eligible for any cash return of investment under the terms of the
previously agreed upon and attached DRIP Plan, should NutraPharma so chose,
until March 15, 2006 or a minimum of one year after the final payment of its
investment.

If the minimum of the above stated investment timeline is not adhered to by the
Investor then XenaCare will have the full rights to adjust the total amount of
investment managed offices from 15 to whatever the total may equitably be based
on the costs of the Sites of Care and lost opportunity costs at the time of the
final investment.

On it's part, NutraPharma agrees to provide XenaCare on a timely basis support
in identifying and enrolling Site of Care Physicians for purposes of management
of the investment. Should NutraPharma not effectively assist XenaCare in
identifying and enrolling Site of Care Physicians then XenaCare shall deduct the
cost of said service from NutraPharma's original investment as a cost of
managing NutraPharma's Investment.

If NutraPharma fulfills it's total investment obligation by no later then
February 15, 2005, participates in the DRIP plan and assists in identifying and
enrolling participation SOC physicians, and only if the original investors are
given an opportunity to participate in a second round of financing, then
NutraPharma shall be eligible for participation in the second round of financing
opportunity in a plan consistent with the original investors.

Should a second round of financing occur, and NutraPharma achieves eligibility
then NutraPharma will have a 30 day notice to participate. NutraPharma's current
investment carries no voting privileges and therefore under no circumstances can
NutraPharma block any future rounds of financing that XenaCare may wish to
participate in.

If this agreement accurately summarizes the terms of our earlier agreements
(attached) and conversations, please sign below on this and the attached copy.
Please also sign the Dividend Reinvestment Agreement. Retain one copy for your
records and return one signed copy to me. My email address is
Axenakismd@xenacare.com. My fax number is 561-999-9086.

Sincerely,

Alan P. Xenakis, MD, Sc.D, MPH
CEO/President

Encl.

Page three - Letter of Intent, September 28, 2004

The undersigned agree to the terms and conditions set forth in this document and
are authorized to execute this Letter of Agreement.

XenaCare, LLC                                        NutraPharma
By:/s/Alan P. Xenakis, MD_                           By:/s/ Rik J. Deitsch
Print Name: Alan P. Xenakis, MD                      Print Name:  Rik J. Deitsch, Ph.D.
Title: CEO, Founder and Managing Partner             Title:  CEO
Date:11/1/2004                                       Date:11/1/2004

                                   Schedule A
                      Nutra Pharma Site Of Care Investment

Parties
     XenaCare LLC, A Delaware Corporation ("Manager"), agrees to manage the
     $250,000 investment from Nutra Pharma ("Investor") in XenaCare's Site of
     Care Physician Development Program on the following terms:

The Manager
1.   XenaCare, LLC is a rapidly growing national healthcare limited liability
     company (the "Manager") under and pursuant to Title 6 Chapter 18 of the
     Delaware Code (the Delaware Limited Liability Company Act). The Manager
     received a certificate of formation that was executed and filed with the
     Delaware Secretary of State on the 20th day of December, 2001 pursuant to
     Section 18-20 of the Delaware Limited Liability Company Act. The Manager
     operates as a healthcare management services and product company with
     exclusive contract, lease rights and privileges within physician offices
     (Sites of Care) for providing to patients the benefits of protocol and
     product development technologies, as well as the expertise to supervise
     and/or manufacture, distribute, sell and/or resell FDA guideline supported
     non-prescription pharmaceuticals, tests, personnel and other related
     services. The Manager currently primarily operates in New York and Florida
     with its Corporate office located at 7700 Congress Avenue, Suite 3208, Boca
     Raton, Florida, 33487

Purpose
2.   The Site of Care (SOC) Investment Plan ("Plan") provides a method and
     opportunity for the Investor to Invest $250,000 into the opening of Fifteen
     (15) new SOC without payment of brokerage, management or service charges.

Benefits
     The requirement for investment in each Site of Care is $16,668 (15 SOC
     require $250,000) as per Schedule A, Exhibit 1. The Cost Requirement for
     the Manager to identify, market, cluster and contract fifteen (15) eligible
     SOC for the Plan is normally $37,500 ($2,500 per office). This Cost
     Requirement is waived for the Investor under the terms of the initial 15
     offices. The Investor has declared  that it wishes to take the  Dividends
     from each SOC and reinvest the dividends back into new SOC openings as per
     Schedule B.

SOC Operation
3.   The Manager shall manage all new Sites of Care to maximize their
     productivity and effectiveness. Every reasonable attempt will be made to
     have the Investor's invested SOC care reach profitability and achieve
     dividend projections based on a resource based relative value scale as

                       XenaCare_____    Nutra Pharma_____
                                                                               1

Maintenance SOC
     depicted in Schedule A, Exhibit 3, Resource Based Relative Value Evaluation
     and Schedule A, Exhibit 4, Dividend Schedule. If however, an SOC, for
     reasons not the fault of the Manager, becomes unfavorable to Administrate
     and Operate as determined by the Manger with a full-time Nurse Educator
     then the Investor shall continue to receive its Dividend from its
     Investment for as long as sold NPP's generate revenue from the SOC. This
     SOC shall be designated as a Maintenance SOC.

     There are no brokerage commissions, service charges or management fees for
     the Manager to administrate the resource based relative value plan.

     The Investor shall receive quarterly statements as to all Sites of Care
     that it has an Investment in as well as the status and schedule for the
     reinvestment of all dividend assets generated from its original investment.

     Participation in an Invested SOC may be terminated at any time by the
     Investor. Cancellation shall become effective 60 days after certified mail
     Receipt by the Manager of such a cancellation.

Non-Assignability
4.   The Right to participate in the Resource Based Relative Value Plan is not
     assignable by the Investors to any other entity

Purchase Price
5.   The purchase price of the original 15 Sites Of Care purchased by the
     Manager on behalf of the Investor is $16,668 per Site of Care. The Investor
     will not be charged any brokerage or management fee as outlined in
     paragraph 2. Dividends will be accrued by the Manager for full reinvestment
     under terms of Schedule B.

Administration
6.   The Resource Based Relative Value Plan shall be administered on behalf of
     the Investor by the Manager and shall report to the Investor on a regular
     basis. All administrative costs of the Plan, including expenses of the
     Manager, shall be paid by the Manager.

Reports
7.   Statements will be sent to the Investor on a quarterly basis by the
     Manager. The statements will set out the Site of Care opening record date,
     the dividend status, the amount of cash dividend available for
     reinvestment, and applicable withholding taxes. These statements are an
     Investor's continuing  record of its initial investment and status of its
     dividends and their reinvestment. In addition, the Investor will be sent
     annually the appropriate information for income tax reporting purposes.

                       XenaCare_____    Nutra Pharma_____
                                                                               2

                                   Schedule B
                     Nutra Pharma Dividend Reinvestment Plan

     XenaCare LLC, A Delaware Corporation ("Manager")  agrees to manage the
     Dividend Reinvestment of a $250,000 investment from Nutra Pharma
     ("Investor") in XenaCare's Site of Care Physician Program on the following
     terms:

The Manager
1.   XenaCare, LLC is a rapidly growing national healthcare limited liability
     company (the "Manager") under and pursuant to Title 6 Chapter 18 of the
     Delaware Code (the Delaware Limited Liability Company Act). The Manager
     received a certificate of formation that was executed and filed with the
     Delaware Secretary of State on the 20th day of December, 2001 pursuant to
     Section 18-20 of the Delaware Limited Liability Company Act. The Manager
     operates as a healthcare management services and product company with
     exclusive contract, lease rights and privileges within physician offices
     (Sites of Care) for providing to patients the benefits of protocol and
     product development technologies, as well as the expertise to supervise
     and/or manufacture, distribute, sell and/or resell FDA guideline supported
     non-prescription pharmaceuticals, tests, personnel and other related
     services. The Manager currently primarily operates in New York and Florida
     with its Corporate office located at 7700 Congress Avenue, Suite 3208, Boca
     Raton, Florida, 33487

Purpose
2.   The Site of Care Reinvestment Plan ("Plan") provides a method and
     opportunity for the Investor to  reinvest all of it's earned cash assets
     from the previously invested $250,000 in the original fifteen(15) SOC's
     into the opening of new SOC or maximizing already existing SOC without
     payment of any brokerage, management or service charges for the first 15
     offices.

     The declaration of the available dividend assets to the Investors for
     reinvestment is at the discretion of the Manager. Dividend payment dates
     for the original investment are expected quarterly from time of first
     investment Site of Care Opening.

Benefits
3.   The reinvestment price for new Sites of Care or maximizing existing Sites
     of Care on behalf of the Investor shall be the cost of Opening a New Site
     of Care or maximizing that Site of Care at the time of the dividend
     reinvestment. The requirement of the reinvestment shall be set at 100% of
     the cost that would be required if the Manager were to open or maximize the
     Site of Care with its own investment.

                       XenaCare_____    Nutra Pharma_____
                                                                               1

     There are no brokerage commissions, service charges or management fees for
     the Manager to administrate the plan for the initial 15 offices. XenaCare
     reserves the right to assess the Investor fair and customary management
     fees to cover the Cost Requiremen for the Manager to identify, market,
     cluster and contract a new SOC opened beyond the original 15. Full
     investment of dividends is achieved when the plan accrues the Investor
     assets and reinvests at the point the Dividend reaches the requirement
     necessary to fund the opening of a new Site of Care.

     The Investor shall receive quarterly statements as to all Sites of Care
     that it has an Investment in as well as the status and schedule for the
     reinvestment of all dividend assets generated from its original investment.

     Participation in the Plan may be terminated at any time by either party.
     Cancellation shall become effective 60 days after certified mail receipt by
     the Manager or Investor of such a cancellation.

Non-Assignability
4.   The Right to participate in the Plan is not assignable by the Investors to
     any other entity

Method of Dividend Reinvestment
5.   The Investor's dividend assets shall be reinvested at 100% of their cash
     value after deduction of any applicable withholding tax. The Investor will
     be credited with the number of Sites of Care from its original Investment
     (15) and any new Sites of Care equal to the dividends reinvested for 95% of
     the cost of such openings.

Purchase Price
6.   The purchase price of Sites Of Care purchased by the Manager on behalf of
     the Investor with reinvested dividends will be 95% of the cost that would
     be required if the Manager, at the time of the reinvestment, were to open
     or maximize the Site of Care with its own investment. The Investor will not
     be charged any brokerage or management fee. Dividends will be accrued by
     the Manager until full investment for each new Site of Care is attained.

Fractional Assets utilization
Reinvestment SOC Dividend Eligibility
7.   It is to the benefit of both the Manager and the Investor to open Sites of
     Care as soon as possible. The Manager then has the discretion to utilize
     the Investor's fractional dividend assets to assist in the opening of a new
     Site of Care. Upon the time that the Investor has dividend assets in
     aggregate from any combination of the original SOC which achieve 95% of the
     cost of opening the new SOC, then the reinvested SOC will immediately be
     deemed eligible for the Investor accrue new  dividend assets from said
     reinvestment SOC. Unless notified in writing from the Investor, said new
     accrued dividend assets from reinvestment SOC's will be utilized by the
     Manager to assist in the opening of another new SOC.

Dividend Reinvestment Term
8.   The Term for eligibility for reinvestment from SOC dividends from this
     agreement shall be for a period of three (3) years from the date of this

                       XenaCare_____    Nutra Pharma_____
                                                                               2

Right to Change Initial Reinvestment Charge
     contract. Excluding the original fifteen (15) SOC any reinvestment into a
     new SOC may at the  Manager's discretion reflect new operations initial
     opening costs. Under these circumstances the cost to the Investor to
     reinvest in a new SOC may exceed $16,668 to achieve 95% of the cost of
     opening the new SOC. If this situation occurs then the Manager will share
     this cost information with the Investor and give the investor the right of
     refusal within 30 days to reinvest  into a new SOC at said elevated
     reinvestment cost or take the dividend in question as cash.

Administration
     The Plan shall be administered on behalf of the Investor by the Manager and
     shall report to the Investor on a regular basis. All administrative costs
     of the Plan, including expenses of the Manager, shall be paid by the
     Manager.

Statements and Reports
9.   Statements will be sent to the Investor on a quarterly basis by the
     Manager. The statements will set out the Site of Care opening record date,
     the dividend status, the amount of cash dividend available for
     reinvestment, and applicable withholding taxes. These statements are an
     Investor's continuing record of its initial investment and status of its
     dividends and their reinvestment. In addition, the Investor will be sent
     annually the appropriate information for income tax reporting purposes.

     Please sign the following Dividend Schedule you wish the Manager to manage
     for you:

     I  ____________________ Accept the terms of Schedule B of Dividend
     Reinvestment and Refuse the option of Dividend Cash Return in Schedule C at
     this time.

     I  ____________________ Refuse the terms of Schedule B of Dividend
     Reinvestment and Accept the option of Dividend Cash Return in Schedule C at
     this time

                                   Schedule C
                           NutraPharma Dividend Return

     XenaCare LLC, A Delaware Corporation ("Manager"), agrees to manage the
     $250,000 investment from NutraPharma ("Investor") in XenaCare's Site of
     Care (SOC) Physician Development Program (Plan) on the following terms:

The Manager
1.   XenaCare, LLC is a rapidly growing national healthcare limited liability
     company (the  "Manager") under and pursuant to Title 6 Chapter 18 of the
     Delaware Code (the Delaware Limited Liability Company Act). The Manager
     holds a certificate of formation that was executed and filed with the
     Delaware Secretary of State on the 20th day of December, 2001 pursuant to
     Section 18-20 of the Delaware Limited Liability Company Act.

     The Manager operates as a healthcare management services and product
     company with exclusive contract, lease rights and privileges within
     physician offices (SOC) for providing to patients the benefits of protocol
     and product development technologies, as well as the expertise to supervise
     and/or manufacture, distribute, sell and/or resell FDA guideline supported
     non-prescription pharmaceuticals, tests, personnel and other related
     services. The Manager currently primarily operates in New York and Florida
     with its Corporate office located at 7700 Congress Avenue, Suite 3208, Boca
     Raton, Florida, 33487

Purpose
Plan Benefits and Waived Total Cost Requirement
2.   The Plan provides a method and opportunity for the Investor to Invest
     $250,000 into the opening of fifteen(15) new SOC without payment of any
     brokerage, management or service charges. The investment requirement for
     the Plan in each SOC is $16,668 as per Schedule A, Exhibit 1. The
     requirement for investment in each Site of Care is $16,668 (15 SOC require
     $250,000) as per Schedule A, Exhibit 1. The Cost Requirement for the
     Manager to identify, market, cluster and contract fifteen (15) eligible SOC
     for the Plan is normally $37,500 ($2,500 per office). This Total Cost
     Requirement will be waived for the Investor under the terms of the initial
     opening of the first 15 SOC. The Investor has declared that it wishes to
     take the Dividends from each SOC and reinvest the dividends back into new
     SOC openings as per Schedule B.

Dividend Return Schedule
3.   By signing this Schedule the Investor wishes to take the dividends from
     each invested SOC as return on a cash scheduled basis.

                       XenaCare_____    Nutra Pharma_____
                                                                               1

Dividend Accounting and Investor Payout
     The Investor shall become eligible for cash return on its dividends for
     each of the fifteen (15) Invested SOC 90 days from the start date of each
     SOC opening. Each 30 days thereafter, the Investor shall receive the
     appropriate earned dividend from each eligible SOC. At the close of each
     month after the initial 90 days from the start of each  invested SOC, the
     dividend accrued from the SOC shall be accounted for and the appropriate
     dividend earnings shall be mailed to the Investor within fourteen days of
     the month's close.

SOC Operation
4.   The Manager shall manage all new SOC to maximize their productivity and
     effectiveness. Every reasonable attempt will be made to have the Investor's
     SOC reach profitability and achieve dividends based on a resource based
     relative value scale as depicted in Schedule A, Exhibit 3, and Schedule A,
     Exhibit 4, Dividend Schedule. If however, an SOC, for reasons not the fault
     of the Manager, becomes unfavorable to administrate and operate as
     determined by the Manger with a full-time Nurse Educator then the Investor
     shall continue to receive its dividend from the Plan for as long as sold
     NPP's generate revenue from  the SOC. The SOC so involved shall  be
     designated as a Maintenance SOC.

Maintenance SOC
     There are no brokerage commissions, service charges or management fees for
     the Manager to administrate the Plan.

     The Investor shall receive quarterly statements as to all SOC that it has
     an Investment in. The Investor, if applicable, shall also receive quarterly
     schedules for the reinvestment of all dividend assets generated from its
     original investment.

Cancellation
     Participation in an Invested SOC may be terminated at any time by the
     Investor. Cancellation shall become effective 60 days after certified mail
     receipt by the Manager of such a cancellation. At no time is the Manager
     liable for the Investor's investment nor is the Investor eligible for a
     refund of their investment.

Non-Assignability
5.   The Right to participate in the Plan is not assignable by the Investors to
     any other entity

Investment Price
6.   The investment price for the original fifteen 15 SOC paid to the Manager
     for the Plan on behalf of the Investor is $16,668 per SOC. For purposes of
     this Plan only, the Investor will not be charged any brokerage fee above
     the $16,668 per SOC. As advised by the Investor at the onset of this
     contract in writing, dividends will be accrued by the Manager for full
     reinvestment under terms of Schedule B.

Applicable Dividend Taxes
7.   Plan of this agreement shall be administered on behalf of the Investor by
     the Manager and shall report to the Investor on a regular basis. All

                       XenaCare_____    Nutra Pharma_____
                                                                               2

     administrative costs of the Plan, including expenses of the Manager, shall
     be paid by the Manager. However any and all taxes applicable to Investor
     earned dividends shall be the sole responsibility of the Investor.

Statements and Reports
8.   Statements will be sent to the Investor on a quarterly basis by the
     Manager. The statements will set out the SOC opening record date and the
     dividend status paid to date and applicable withholding taxes. These
     statements are an Investor's continuing record of its initial investment
     and status of its dividends. In addition, the Investor will be sent
     annually the appropriate information for income tax reporting purposes.

     Please sign the following Dividend Schedule you wish the Manager to manage
     for you:

     I  ____________________ refuse the terms of Schedule C of Cash Return on
     Dividends and Accept the option of Dividend Reinvestment in Schedule B at
     this time

     I  ____________________ accept the terms of Schedule C of Cash Return on
     Dividends and Refuse the option of Dividend Reinvestment in Schedule B at
     this time

                       XenaCare_____    Nutra Pharma_____
                                                                               3Exhibit 10.11 Nutra Pharma Corp.

Exhibit 10.11 Nutra Pharma Corp.

AGREEMENT FOR RESEARCH SERVICES

THIS AGREEMENT is by and among Nutra Pharma Corp., a California corporation with
principal executive offices located at 4001 NW 73rd Way, Coral Springs, Florida
33065 ("Nutra Pharma") and Eno Research and Development, Inc. ("ERDI"), located
at P.O. Box 1522, Hillsborough, NC 27278.

1. Terms and Duties

Nutra Pharma wishes ERDI to conduct, and ERDI hereby agrees to conduct research
on drug delivery technology ("plantumans") from Portage BioMed for a period of
one (1) year, commencing on the date this agreement is fully executed
("Effective Date") and terminating one year later.

In consideration of the payment provided herein, Nutra Pharma agrees to the
following conditions:

a. Nutra Pharma, through Portage BioMed, shall provide ERDI with a sufficient
number of plantumans for the proposed research ("Samples"). Research will be
performed according to the proposal listed in Appendix A, which is attached
hereto and incorporated herein by reference and which may be modified by mutual
written agreement from time to time. Any amendments to the Study and extent
thereof shall be mutually agreed in writing between the Official Correspondents
to this agreement, as the Study progresses. Such Samples, or any derivative
thereof, should not be used for any other purpose other than Study as stated in
such proposal and are provided without warranty of merchantability or fitness
for any particular purpose.
b. The Study will be performed at an ERDI laboratory or facility contracted by
ERDI. Nutra Pharma warrants that the Samples are not in violation of any third
party agreement or obligation. ERDI represents that the obligations undertaken
by ERDI under this Agreement are not in conflict with any third party agreement
or obligation.
c. ERDI agrees that the samples will not be administered to humans.
d. The term "ERDI" as used herein, shall be deemed to include Investigators and
any agents, employees and technicians ERDI utilizes in the performance of this
Agreement. The obligations and representations ERDI makes hereunder are also
imposed on the agents, employees and technicians of ERDI. ERDI shall advise such
persons of these obligations and representations.
e. Rik J. Deitsch shall be the Official Correspondent for Nutra Pharma. In the
event that ERDI needs to correspond with other Nutra Pharma personnel, a copy of
such correspondence shall be sent to Nutra Pharma's Official Correspondent at
the address above. In a similar fashion, ERDI's Official Correspondent shall be
James L. Flowers. In the

                                     - 1 -

event that Nutra Pharma needs to correspond with other ERDI personnel, a copy of
such correspondence shall be sent to ERDI's Official Correspondent at the
address listed above.
f. ERDI shall provide Nutra Pharma with a final written report ("Final Report")
within thirty (30) days of completion of the Study. Nutra Pharma shall keep such
final written report confidential until the earlier of: (i) publication of the
Study by results by ERDI, as described herein; or (ii) five (5) years from the
termination or expiration of this Agreement, unless mutually agreed to in
writing by the Official Correspondents for this Agreement.

2. Compensation

a. For Phase I of this study as outlined in Appendix A, Nutra Pharma agrees to
pay ERDI a sum based on the cost of the Study, up to a maximum of Thirty Two
Thousand Dollars ($32,000.00) for the Study under this Agreement. The full sum
is due upon execution of this contract. Upon receipt of this payment, ERDI will
commence work on Phase I of this Study. Completion of Phase I marks Decision
Point 1 (DP1) for this Study. Should the Study be considered "successful" by
Nutra Pharma (with input from Portage BioMed), the Study will proceed to Phase
II as described in Appendix A. For Phase II of this study as outlined in
Appendix A, Nutra Pharma agrees to pay ERDI a sum based on the cost of the
Study, up to a maximum of Thirty Five Thousand Dollars ($35,000.00) for this
Phase of the Study under this Agreement. The full sum is to be paid before work
on Phase II can commence. This Study is expected to take 5 - 7 weeks to
complete. The actual total payment shall reflect the research completed under
this Agreement. In the event of early termination, costs shall be determined as
per Article 9.
b. As an independent contractor, ERDI shall be responsible for withholding and
payment of any and all income taxes and social security contributions that may
be required.
c. Further compensation, if required, shall be agreed in writing between the
parties.

3. Confidential Matters

a. ERDI shall keep in confidence all information relating to this Agreement
which may be acquired from Nutra Pharma in connection with the Study
("Information"). During the term of this agreement and for five (5) years
thereafter, without prior written consent of Nutra Pharma, neither ERDI nor any
of its agents or employees shall publish, communicate, divulge, disclose, or use
any of such Information acquired from Nutra Pharma which has been designated by
Nutra Pharma as

                                     - 2 -

proprietary Information. Upon termination or expiration of this Agreement, ERDI
shall deliver all such Information and copies thereof to Nutra Pharma and such
shall remain property of Nutra Pharma, save for one copy to be retained by ERDI
to ensure compliance with the duty of confidentiality.
b. Nothing in this Article 3 and Article 4, below, shall be construed to impose
a confidentiality obligation on ERDI in connection with any information to the
extent such information: (i) is at the time of disclosure already known to ERDI
on a non-confidential basis as clearly demonstrated by ERDI records; (ii) is at
the time of disclosure or subsequently becomes part of the public domain through
no fault or act of omission by ERDI; (iii) is subsequently disclosed to ERDI by
a third party whose receipt and disclosure of such information does not
constitute a violation of any confidentiality obligation; or (iv) is
independently developed by ERDI, as evidenced by its written records.
c. In the event that ERDI is requested by a court of law or regulatory agency to
provide Information, ERDI shall immediately notify Nutra Pharma and reasonably
co-operate with Nutra Pharma's efforts to obtain any and all protections
available for such Information prior to any such requested disclosure.

The obligations imposed on ERDI by this Article 3 and by Article 4, below, shall
survive any termination or expiration of this Agreement and the termination of
ERDI services hereunder.

4. Ownership

a. Nutra Pharma shall be free to use the results of this Study for its own
purposes, subject to any intellectual property rights that ERDI may have.
b. ERDI shall promptly and confidentially disclose to Nutra Pharma all
inventions, developments or discoveries that are made during the course of and
arise from the Study ("Inventions"). Ownership of such Inventions shall reflect
inventorship as determined by U.S. patent law, if patentable, and shall be
determined by mutual consent between the parties if not patentable. Nutra Pharma
shall have, without option fee other than the reimbursement of all patent
expenses for the subject Invention incurred prior to and during the option
period and appertaining license negotiation period, a first option to acquire an
exclusive worldwide royalty-bearing license to ERDI's rights in any Inventions.
Such option shall extend for ninety (90) days from the date of disclosure to
Nutra Pharma. Upon Nutra Pharma's exercise of its option, the parties shall
negotiate a license agreement in good faith.
c. ERDI shall be free to use the results of the Study for publication purposes
without the payment of royalties or other fees. Collaboration

                                     - 3 -

between ERDI and Nutra Pharma on any publication shall be sufficient to allow
one or more Nutra Pharma representatives authorship on said publication. ERDI
shall submit a copy of any proposed publication resulting from the study to
Nutra Pharma for review at least thirty (30) days prior to submission to a
publisher thereof. If Nutra Pharma determines that the proposed publication
contains subject matter requiring patent protection, then ERDI shall delay
publication for up to an additional sixty (60) days for the filing of patent
applications. Such publication shall not contain any Information provided by
Nutra Pharma without the prior written consent of Nutra Pharma.
d. Any abstracts or seminars pertaining to the results of the Study prior to
publication shall be made by representatives of ERDI after the content of said
abstract or seminar has been approved by Nutra Pharma. Preparation of the
presentation should follow the rules set for publication as described above.

5. Disclaimer

a. Nutra Pharma provides the Samples with the understanding that the Samples are
derived from human cell lines and DNA and as such could be inherently dangerous.
All reasonable and necessary precautions should be taken in the handling of
these Samples. It is Nutra Pharma's understanding that ERDI and its personnel
are skilled in the handling of such Samples. Nutra Pharma assumes no
responsibility or liability for any injury or harm caused by the handling of
such Samples, except for any such liability that may be traced to Nutra Pharma's
gross negligence or intentional malfeasance.
b. ERDI will defend and hold harmless Nutra Pharma, its officers, directors,
employees and agents from any claims for personal injury, death or property
damage arising out of ERDI's negligence or willful misconduct in connection with
the performance of this agreement.
c. Nutra Pharma acknowledges that ERDI may not know the therapeutic use that the
results of any study will be used for and acknowledges that ERDI has no control
over Nutra Pharma's use of such results. Nutra Pharma shall, therefore,
indemnify and hold ERDI, its officers, directors, agents, employees and
affiliates, harmless from any claim, liability, or expense arising directly or
indirectly from ERDI's association with Nutra Pharma as the result of this
Agreement and the Study, including, without limitation, any claim, liability or
expense arising out of the harmful or otherwise unsafe affect of the Study
materials or Nutra Pharma's use of the Study or its use for marketing of any
Study materials.

6. General Relationship

                                     - 4 -

In all matters relating to this agreement, ERDI acts as an independent
contractor. Neither ERDI nor ERDI employees are employees of Nutra Pharma under
the meaning or application of any federal or state unemployment or insurance
laws or worker's compensation laws, or otherwise. ERDI shall assume all
liabilities or obligations imposed by any one or more of such laws with respect
to the negligence or willful misconduct of ERDI employees in their performance
of this Agreement. ERDI shall not have any authority to assume or create any
obligation, express or implied, on behalf of Nutra Pharma and ERDI shall have no
authority to represent itself as an agent, employee, or in any other capacity of
Nutra Pharma. Nutra Pharma shall not, without prior written permission of ERDI,
use in advertising, publicity or otherwise, the name, symbol, logo or other
image of ERDI or ERDI's employees or agents.

7. Non-Assignability

In view of the specific nature of the Study to be performed by ERDI hereunder,
ERDI shall not have the right to assign or transfer any of its obligations,
rights or benefits hereunder without the prior written consent of Nutra Pharma.
However, Nutra Pharma may assign this Agreement to an Affiliate or to a
purchaser of all or substantially all of the business to which it pertains.
"Affiliate" shall mean any company directly or indirectly controlled or under
common control with Nutra Pharma. For this purpose, the terms "controlling",
"controlled", and "control" shall mean ownership, directly or indirectly, of at
least fifty percent (50%) or the maximum percentage allowed by law in the given
country, of the voting stock or general partnership interests of such
corporation, partnership or other entity.

8. Superseding Effect

This Agreement supersedes all prior oral or written agreements, if any, between
the parties relating to matters subject to this Agreement, and constitutes the
entire agreement between the parties. This Agreement may not be amended or
supplemented except by a writing signed by each of the parties.

9. Termination

Both parties reserve the right to cancel this Agreement for any reason upon
thirty (30) days prior written notice to the other party. If this Agreement is
so terminated, Nutra Pharma shall be liable only for payment for services
performed, costs incurred or irrevocably obligated and travel approved and
undertaken prior to the effective date of termination; provided, however, that
ERDI shall not be liable to return to Nutra Pharma any amount received prior to
the effective date of termination. Upon such termination, ERDI shall provide a
summary of all Study

                                     - 5 -

results to the date of termination to Nutra Pharma, and copies of the original
data as requested by Nutra Pharma.

10. Force Majeure

Either party shall be excused from performing its obligations with respect to
this Agreement if its performance is delayed or prevented by any cause beyond
such party's control, including, but not limited to, acts of God, fire,
explosion, weather, disease, war, insurrection, civil strife, riots, government
action, or power failure. Performance shall be excused only to the extent of and
during the reasonable continuance of such disability. Any deadline or time for
performance that falls due during or subsequent to the occurrence of any of the
disabilities referred to herein shall be automatically extended for a period of
time equal to the period of such disability. ERDI will immediately notify Nutra
Pharma if, by reason of any of the disabilities referred to herein, ERDI is
unable to meet any deadline or time for performance.

11. Applicable Law

The law of the State of North Carolina shall govern any controversy or claim
arising out of or relating to this Agreement. The parties agree that any action
or proceeding arising out of or related to this Agreement shall be brought only
in the state or federal courts located in North Carolina. The parties hereby
consent to such venue and to the jurisdiction of such courts over the subject
matter of such proceedings and themselves.

                                     - 6 -

IN WITNESS WHEREOF the parties hereto executed this Agreement below.

NUTRA PHARMA CORPORATION

By: /s/ Rik J. Deitsch

Name: Rik J. Deitsch
Title: President, CEO

Date: November 24, 2004

ENO RESEARCH & DEVELOPMENT INCORPORATED

By: /s/James L. Flowers

Name: James L. Flowers
Title: President, Chief Scientific Officer

Date: November 24, 2004

                                     - 7 -

Appendix A

Phase I of 4 Step Characterization Process as presented to Portage BioMed

1. Characterization of "Plantumans"
        A novel cell such as this must be characterized.
                * Scanning electron, light and fluorescence microscopy for
                  cellular composition and structure.
                * Differential centrifugation to separate organelles
                * Cytogenetics to determine genetic composition (human vs plant
                  chromosomes in the "plantuman")

2. Measure "Plantumans" drug absorption / release kinetics
        Use 5-class chemotherapeutic screen: 5-FU (DNA antimetabolite), Taxol
        (microtubule agent), CPT-11 (TopoI inhibitor), Adriamycin (TopoII
        inhibitor) and Cytoxan (alkylator)
                * Measure chemo uptake into "plantumans" over time by HPLC,
                  UV-Vis, fluorometery
                * Measure chemo retention over time in buffer and plasma by
                  HPLC, UV-Vis, fluorometery
                * Measure viability over time as a function of "plantuman"
                  exposure to chemo by MTS, calcein, trypan.

3. Evaluate selectivity of "plantumans" for cancer cells
        Using ERDI's proprietary Tumor Specificity Assay to evaluate effect
        of empty and loaded "plantumans" on normal and tumor cells at the same
        time in multiple cancer lines

                Prostate
                Breast
                Neuro
                Ovarian
                Lung
                Epithelial

Phase II

4. Mouse Study
        10 mice per group, endpoint is time for tumor to grow to five-times
        initial volume or 5 weeks, whichever comes first

        Option 1: 5 Groups - Untreated Control, Vehicle control, "plantumans"
        + vehicle, vehicle + drug, "plantumans" + vehicle + drug
        Option 2: 7 Groups - Add second concentration of drug to demonstrate
        dose dependence of system.

                                     - 8 -

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00076-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00076-of-00352.parquet"}]]